Bristol to invest $2 mil. in Houghten drug discovery collaboration by project end, lawsuit discloses.
Executive Summary
BRISTOL TO INVEST $2 MIL. IN HOUGHTEN DRUG DISCOVERY COLLABORATION upon completion of the project, which applies Houghten Pharmaceuticals Inc. subsidiary ChromaXome's combinatorial biology to Bristol-Myers Squibb's microbe library for screening of new drug leads, according to statements made in an Oct. 7 lawsuit. The wrongful termination of employment suit was brought by ChromaXome's founders against Houghten and filed in San Diego federal court.You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: